B-9135 Birinapant, Free Base, >99%

Synonyms : [TL-32711]

  • Size
  • US $
  • £
  • ¥
  • 5 mg
  • 74
  • 66
  • 57
  • 8,200
  • Add to Cart Qty:
  • In stock
  • 10 mg
  • 111
  • 99
  • 86
  • 12,400
  • Add to Cart Qty:
  • In stock
  • 25 mg
  • 199
  • 177
  • 155
  • 22,100
  • Add to Cart Qty:
  • In stock
  • 50 mg
  • 284
  • 253
  • 221
  • 31,600
  • Add to Cart
  • Out of stock
  • 100 mg
  • 472
  • 421
  • 368
  • 52,500
  • Add to Cart
  • Out of stock

Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.

To receive a Quotation for catalog sizes of this product and/or any other products, please add them to your shopping cart and click on the “REQUEST A QUOTATION” box.
Click Here to Request a Quotation for Larger Quantities Click Here to see what Shipping and Handling Costs would be to Your Country
  • M.W. 806.94
  • C42H56F2N8O6
  • [1260251-31-7]

  • Birinapant, also known as TL32711, is an antagonist for the inhibitor of apoptosis protein (IAP). IAP promotes cancer cell survival and confers resistance to cancer therapy.
  • Birinapant induced apoptosis and enhanced TRAIL potency in inflammatory breast cancer cells. Allensworth J.L., et al. "Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism." Breast Cancer Res. Treat. 137: 359-371 (2013).
  • Birinapant in combination with TNF-[alpha] exhibited a strong anti-tumor effect in 12 of 18 melanoma cell lines and was effective in a melanoma cell line with acquired resistance to BRAF inhibitors. Krepler C., et al. "The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells." Clin. Cancer Res. 19: 1784-1794 (2013).
  • Birinapant, a bivalent SMAC mimetic, targeted TRAF2-associated cIAP1 and cIAP2, blocked TNF-induced NF-κB activation, and was active in multiple primary patient-derived xenograft models. Benetatos C.A., et al. "Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-κB Activation, and Is Active in Patient-Derived Xenograft Models." Mol. Cancer Ther. 13: 867-879 (2014).
  • Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
  • This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
  • Not available in some countries; not available to some institutions; not available for some uses.
544